cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alkermes Plc
7 own
15 watching
Current Price
$31.19
$-0.56
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,684.81M
52-Week High
52-Week High
32.88000
52-Week Low
52-Week Low
22.90000
Average Volume
Average Volume
1.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,684.81M
icon52-Week High32.88000
icon52-Week Low22.90000
iconAverage Volume1.67M
iconDividend Yield--
iconP/E Ratio--
What does the Alkermes Plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
How much money does Alkermes Plc make?
News & Events about Alkermes Plc.
PR Newswire
1 year ago
Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders PR Newswire DUBLIN, June 29, 2023 No Sarissa Nominees Elected by...
Accesswire
1 year ago
NORTHAMPTON, MA / ACCESSWIRE / June 27, 2023 / AlkermesA one-size-fits-all approach to mental health care does not work for everyone in the LGBTQ+ community. Each sub-community faces unique challenges. Check out these tips from NAMI if you or someone you care about is seeking LGBTQ+ competent...
Accesswire
1 year ago
NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Alkermes:This PrideMonth, Alkermes honors the resiliency of the LGBTQ+ community. We're committed to fighting the stigmas that may contribute to substance abuse and may act as barriers to receiving treatment. View additional multimedia and more ESG...
Business Wire
1 year ago
Sarissa Capital Management LP (Sarissa) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS): We are pleased that ISS recognizes the...
Accesswire
1 year ago
NORTHAMPTON, MA / ACCESSWIRE / June 16, 2023 / AlkermesOn Monday we commemorate Juneteenth - also known as Freedom Day - the anniversary of the freeing of the last enslaved Black Americans, which took place on June 19th, 1865, more than two years after President Lincoln issued the Emancipation...
Frequently Asked Questions
Frequently Asked Questions
What is Alkermes Plc share price today?
plus_minus_icon
Can Indians buy Alkermes Plc shares?
plus_minus_icon
How can I buy Alkermes Plc shares from India?
plus_minus_icon
Can Fractional shares of Alkermes Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Alkermes Plc stocks?
plus_minus_icon
What is today’s traded volume of Alkermes Plc?
plus_minus_icon
What is today’s market capitalisation of Alkermes Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Alkermes Plc?
plus_minus_icon
What percentage is Alkermes Plc down from its 52-Week High?
plus_minus_icon
What percentage is Alkermes Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.19
$-0.56
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$44.05
$-0.80 (-1.78 %)
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
$76.68
$-0.05 (-0.07 %)
BorgWarner Inc.
BorgWarner Inc.
$32.65
$0.42 (1.30 %)
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
$38.57
$-0.07 (-0.18 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$44.05
$-0.80 (-1.78 %)
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
$76.68
$-0.05 (-0.07 %)
BorgWarner Inc.
BorgWarner Inc.
$32.65
$0.42 (1.30 %)
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
$38.57
$-0.07 (-0.18 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00